Cerebellar alterations and gait defects as therapeutic outcome measures for enzyme replacement therapy in α-mannosidosis

Markus Damme, Stijn Stroobants, Steven U. Walkley, Renate Lüllmann-Rauch, Rudi D'Hooge, Jens Fogh, Paul Saftig, Torben Lübke, Judith Blanz

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

α-Mannosidosis is a rare lysosomal storage disease with accumulation of undegraded mannosyl-linked oligosaccharides in cells throughout the body, most notably in the CNS. This leads to a broad spectrum of neurological manifestations, including progressive intellectual impairment, disturbed motor functions, and cerebellar atrophy. To develop therapeutic outcome measures for enzyme replacement therapy that could be used for human patients, a gene knockout model of α-mannosidosis in mice was analyzed for CNS pathology and motor deficits. In the cerebellar molecular layer, α-mannosidosis mice display clusters of activated Bergman glia, infiltration of phagocytic macrophages, and accumulation of free cholesterol and gangliosides (GM1), notably in regions lacking Purkinje cells. α-Mannosidosis brain lysates also displayed increased expression of Lamp1 and hyperglycosylation of the cholesterol binding protein NPC2. Detailed assessment of motor function revealed age-dependent gait defects in the mice that resemble the disturbed motor function in human patients. Short-term enzyme replacement therapy partially reversed the observed cerebellar pathology with fewer activated macrophages and astrocytes but unchanged levels of hyperglycosylated NPC2, gangliosides, and cholesterol. The present study demonstrates cerebellar alterations in α-mannosidosis mice that relate to the motor deficits and pathological changes seen in human patients and can be used as therapeutic outcome measures.

Original languageEnglish (US)
Pages (from-to)83-94
Number of pages12
JournalJournal of Neuropathology and Experimental Neurology
Volume70
Issue number1
DOIs
StatePublished - Jan 2011

Fingerprint

Mannosidase Deficiency Diseases
Gait Ataxia
Enzyme Replacement Therapy
Outcome Assessment (Health Care)
Macrophages
Cholesterol
Pathology
Lysosomal Storage Diseases
G(M1) Ganglioside
Therapeutics
Gene Knockout Techniques
Gangliosides
Purkinje Cells
Neurologic Manifestations
Oligosaccharides
Gait
Neuroglia
Astrocytes
Atrophy
Brain

Keywords

  • α-Mannosidase
  • α-Mannosidosis
  • Cerebellar atrophy
  • Enzyme replacement therapy
  • Gait defects
  • Knockout mouse model
  • Lysosomal storage disease

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Clinical Neurology
  • Neurology
  • Cellular and Molecular Neuroscience

Cite this

Cerebellar alterations and gait defects as therapeutic outcome measures for enzyme replacement therapy in α-mannosidosis. / Damme, Markus; Stroobants, Stijn; Walkley, Steven U.; Lüllmann-Rauch, Renate; D'Hooge, Rudi; Fogh, Jens; Saftig, Paul; Lübke, Torben; Blanz, Judith.

In: Journal of Neuropathology and Experimental Neurology, Vol. 70, No. 1, 01.2011, p. 83-94.

Research output: Contribution to journalArticle

Damme, Markus ; Stroobants, Stijn ; Walkley, Steven U. ; Lüllmann-Rauch, Renate ; D'Hooge, Rudi ; Fogh, Jens ; Saftig, Paul ; Lübke, Torben ; Blanz, Judith. / Cerebellar alterations and gait defects as therapeutic outcome measures for enzyme replacement therapy in α-mannosidosis. In: Journal of Neuropathology and Experimental Neurology. 2011 ; Vol. 70, No. 1. pp. 83-94.
@article{91dfe5531dbf4c43843e0081d552a6ca,
title = "Cerebellar alterations and gait defects as therapeutic outcome measures for enzyme replacement therapy in α-mannosidosis",
abstract = "α-Mannosidosis is a rare lysosomal storage disease with accumulation of undegraded mannosyl-linked oligosaccharides in cells throughout the body, most notably in the CNS. This leads to a broad spectrum of neurological manifestations, including progressive intellectual impairment, disturbed motor functions, and cerebellar atrophy. To develop therapeutic outcome measures for enzyme replacement therapy that could be used for human patients, a gene knockout model of α-mannosidosis in mice was analyzed for CNS pathology and motor deficits. In the cerebellar molecular layer, α-mannosidosis mice display clusters of activated Bergman glia, infiltration of phagocytic macrophages, and accumulation of free cholesterol and gangliosides (GM1), notably in regions lacking Purkinje cells. α-Mannosidosis brain lysates also displayed increased expression of Lamp1 and hyperglycosylation of the cholesterol binding protein NPC2. Detailed assessment of motor function revealed age-dependent gait defects in the mice that resemble the disturbed motor function in human patients. Short-term enzyme replacement therapy partially reversed the observed cerebellar pathology with fewer activated macrophages and astrocytes but unchanged levels of hyperglycosylated NPC2, gangliosides, and cholesterol. The present study demonstrates cerebellar alterations in α-mannosidosis mice that relate to the motor deficits and pathological changes seen in human patients and can be used as therapeutic outcome measures.",
keywords = "α-Mannosidase, α-Mannosidosis, Cerebellar atrophy, Enzyme replacement therapy, Gait defects, Knockout mouse model, Lysosomal storage disease",
author = "Markus Damme and Stijn Stroobants and Walkley, {Steven U.} and Renate L{\"u}llmann-Rauch and Rudi D'Hooge and Jens Fogh and Paul Saftig and Torben L{\"u}bke and Judith Blanz",
year = "2011",
month = "1",
doi = "10.1097/NEN.0b013e31820428fa",
language = "English (US)",
volume = "70",
pages = "83--94",
journal = "American Journal of Psychotherapy",
issn = "0002-9564",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Cerebellar alterations and gait defects as therapeutic outcome measures for enzyme replacement therapy in α-mannosidosis

AU - Damme, Markus

AU - Stroobants, Stijn

AU - Walkley, Steven U.

AU - Lüllmann-Rauch, Renate

AU - D'Hooge, Rudi

AU - Fogh, Jens

AU - Saftig, Paul

AU - Lübke, Torben

AU - Blanz, Judith

PY - 2011/1

Y1 - 2011/1

N2 - α-Mannosidosis is a rare lysosomal storage disease with accumulation of undegraded mannosyl-linked oligosaccharides in cells throughout the body, most notably in the CNS. This leads to a broad spectrum of neurological manifestations, including progressive intellectual impairment, disturbed motor functions, and cerebellar atrophy. To develop therapeutic outcome measures for enzyme replacement therapy that could be used for human patients, a gene knockout model of α-mannosidosis in mice was analyzed for CNS pathology and motor deficits. In the cerebellar molecular layer, α-mannosidosis mice display clusters of activated Bergman glia, infiltration of phagocytic macrophages, and accumulation of free cholesterol and gangliosides (GM1), notably in regions lacking Purkinje cells. α-Mannosidosis brain lysates also displayed increased expression of Lamp1 and hyperglycosylation of the cholesterol binding protein NPC2. Detailed assessment of motor function revealed age-dependent gait defects in the mice that resemble the disturbed motor function in human patients. Short-term enzyme replacement therapy partially reversed the observed cerebellar pathology with fewer activated macrophages and astrocytes but unchanged levels of hyperglycosylated NPC2, gangliosides, and cholesterol. The present study demonstrates cerebellar alterations in α-mannosidosis mice that relate to the motor deficits and pathological changes seen in human patients and can be used as therapeutic outcome measures.

AB - α-Mannosidosis is a rare lysosomal storage disease with accumulation of undegraded mannosyl-linked oligosaccharides in cells throughout the body, most notably in the CNS. This leads to a broad spectrum of neurological manifestations, including progressive intellectual impairment, disturbed motor functions, and cerebellar atrophy. To develop therapeutic outcome measures for enzyme replacement therapy that could be used for human patients, a gene knockout model of α-mannosidosis in mice was analyzed for CNS pathology and motor deficits. In the cerebellar molecular layer, α-mannosidosis mice display clusters of activated Bergman glia, infiltration of phagocytic macrophages, and accumulation of free cholesterol and gangliosides (GM1), notably in regions lacking Purkinje cells. α-Mannosidosis brain lysates also displayed increased expression of Lamp1 and hyperglycosylation of the cholesterol binding protein NPC2. Detailed assessment of motor function revealed age-dependent gait defects in the mice that resemble the disturbed motor function in human patients. Short-term enzyme replacement therapy partially reversed the observed cerebellar pathology with fewer activated macrophages and astrocytes but unchanged levels of hyperglycosylated NPC2, gangliosides, and cholesterol. The present study demonstrates cerebellar alterations in α-mannosidosis mice that relate to the motor deficits and pathological changes seen in human patients and can be used as therapeutic outcome measures.

KW - α-Mannosidase

KW - α-Mannosidosis

KW - Cerebellar atrophy

KW - Enzyme replacement therapy

KW - Gait defects

KW - Knockout mouse model

KW - Lysosomal storage disease

UR - http://www.scopus.com/inward/record.url?scp=78650676578&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78650676578&partnerID=8YFLogxK

U2 - 10.1097/NEN.0b013e31820428fa

DO - 10.1097/NEN.0b013e31820428fa

M3 - Article

C2 - 21157375

AN - SCOPUS:78650676578

VL - 70

SP - 83

EP - 94

JO - American Journal of Psychotherapy

JF - American Journal of Psychotherapy

SN - 0002-9564

IS - 1

ER -